Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate

Author: Benzinga Newsdesk | March 07, 2024 05:09pm
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.170) per share which missed the analyst consensus estimate of $(1.150) by 1.74 percent. The company reported quarterly sales of $826.000 thousand which beat the analyst consensus estimate of $1.750 thousand by 47.10K percent. This is a 61.33 percent increase over sales of $512.000 thousand the same period last year.

Posted In: LUMO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist